Evidence map›Paper›PMID 42819322›Full record

ArticleFrontiers in immunology2026

Addition of telitacicept to glucocorticoid reduces abdominal pain duration and relapse rate in children with severe abdominal Henoch-Schönlein purpura: a single-center retrospective matched cohort study.

Xuemei Jiang, Hongye Wang, Mifeng Yang, Xiran Yang, Yabin Liao, Jia Zhang, Jiyu Chen, Helin Yan, Yingyi Zhang, Mengqian Zhouyang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Xuemei Jiang *Nephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.
Hongye Wang *Nephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.
Mifeng Yang *Nephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.
Xiran Yang *Nephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.
Yabin LiaoNephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.
Jia ZhangNephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.
Jiyu ChenNephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.
Helin YanNephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.
Yingyi ZhangNephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.
Mengqian ZhouyangNephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.
Yan GuNephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.
YangCui WeiNephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.
Bo ZhaoNephrology, Rheumatology and Immunology Department, Kunming Children's Hospital, Yunnan Provincial Pediatric Disease Medical Center, Kuming Medical University Affiliated Children's Hospital, Kunming, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Severe abdominal Henoch-Schönlein purpura (HSP) can cause intense abdominal pain and gastrointestinal bleeding. Glucocorticoid therapy has limited efficacy and a high relapse rate after withdrawal. Telitacicept blocks BLyS/APRIL and inhibits the production of pathogenic IgA immune complexes, but its use in HSP has not been reported. Methods: This was a single-center retrospective matched cohort study. Children hospitalized with severe abdominal HSP (abdominal pain VAS ≥3, hematochezia, and extensive rash) between January 2025 and December 2025 were included. Patients were divided into a telitacicept plus glucocorticoid group (telitacicept group) and a glucocorticoid-alone group (steroid group). Individual 1:1 matching was performed based on age, sex, and disease severity. The primary outcome was time to abdominal pain relief. Secondary outcomes included time to rash resolution, disease relapse rate within 3 months after treatment, and safety. Intergroup comparisons used Wilcoxon rank-sum test or Fisher's exact test, and relapse-free time was analyzed by Kaplan-Meier curves and the log-rank test. Results: A total of 26 children (13 per group) were included. Baseline characteristics were balanced between the two groups (age, sex, age strata, all P > 0.05). The median time to abdominal pain relief was 3.0 days (IQR 3.0-4.0) in the telitacicept group, significantly shorter than the 5.0 days (IQR 4.0-6.0) in the steroid group (P = 0.013). Median time to rash resolution was 9.0 days in both groups, with no significant difference (P = 0.113). The 3-month relapse rate was 7.7% (1/13) in the telitacicept group versus 46.2% (6/13) in the steroid group; the log-rank test showed a significant difference in relapse-time distribution (P = 0.022). The number needed to treat (NNT) was 2.6. For safety, mild injection-site redness occurred in 2 patients (15.4%) in the telitacicept group, and transient hyperglycemia occurred in 1 patient (7.7%) in the steroid group. No serious adverse events were observed. Conclusion: In children with severe abdominal HSP, adding telitacicept to glucocorticoid significantly shortens the time to abdominal pain relief and reduces the short-term relapse rate, with a favorable safety profile. This study provides preliminary clinical evidence for telitacicept as an adjunctive therapy to glucocorticoids, which warrants further validation in prospective randomized controlled trials.

Indexed as

Abdominal PainGlucocorticoidsIgA VasculitisAdolescentChildChild, PreschoolDrug Therapy, CombinationFemaleHumansMaleRecombinant Fusion ProteinsRecurrenceRetrospective StudiesSeverity of Illness IndexTreatment OutcomeGlucocorticoidsRecombinant Fusion Proteinstelitaciceptabdominal Henoch-Schönlein purpurachildrenglucocorticoidIgA vasculitismatched cohort studyrelapsetelitacicept

Identifiers

PMID42819322
PMCPMC13623866

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.